Sunitinib is recommended as a possible treatment for people with unresectable or metastatic malignant gastrointestinal stromal tumours if they have already tried imatinib treatment but it has not worked or was not suitable. The manufacturer of sunitinib has agreed to cover the cost of the drug for the first treatment cycle.

Treatment should be supervised by a specialist who is experienced in treating people with gastrointestinal stromal tumours.

  • National Institute for Health and Care Excellence (NICE) accreditation logo